AXXESS Pharma Inc. Signs Agreement With Top Mexican Pharmaceutical Company
September 09 2013 - 3:15PM
Marketwired
Axxess Pharma Inc. (PINKSHEETS: AXXE), a specialty pharmaceutical
and nutritional supplements company, is pleased to announce they
have signed an agreement with a leading Mexican pharmaceutical
company, Industria Farmaceutica Andromaco, S.A. de C.V.
Under the agreement, Axxess Pharma's product, Soropon, will be
marketed in Mexico by Andromaco. Axxess has also secured the rights
to market in Canada, several of Andromaco's market leading
baby-care products.
Axxess's Soropon, a medicated shampoo for the treatment of
cradle cap in infants and a severe form of dandruff in seniors
(Seborrheic dermatitis), fits with Andromaco's core product line
and is anticipated to generate strong sales.
Dr. Daniel Bagi, President of Axxess Pharma, stated: "With a
population three times that of Canada's and a higher birth rate
than Canada's, Axxess is extremely pleased with the market
possibilities in Mexico for Soropon and we anticipate robust sales
for Soropon in Mexico, starting in 2014. Two of Andromaco's baby
care products are among the market leaders in Mexico with annual
sales in excess of ten million dollars (US). Andromaco also
generates sales exporting and selling into the US. These products
are manufactured in Andromaco's US FDA-approved facility. Their
product offerings in infant skin care will add to our OTC infant
skincare product line for the Canadian market."
Mr. Víctor Álvarez, CEO of Andromaco, stated: "Andromaco is very
pleased to start the process towards Canadian sales with Axxess
Pharma for our high-quality infant care products and complete our
goal of selling all across North America."
For more information, please visit www.axxesspharmainc.com, or
contact Investor Relations at (973) 351-3868.
About Axxess Pharma Inc.: Axxess Pharma
Inc. is a Nevada Corporation operating through its wholly-owned
Canadian Subsidiary: Axxess Pharma Canada Inc., headquartered in
Toronto. Axxess is a specialty Health Care Products Company
dedicated to improving health and quality of life by offering
select medicines, nutritional supplements and over the counter
remedies all across the Americas. Axxess's goal is to bring
additional products to the market and provide new, innovative
options for better health spanning areas such as high cholesterol,
blood pressure, acute pain, to optimal health management through
improved nutritional supplements.
Industria Farmaceutica Andromaco, S.A. de
C.V. Andromaco is a well-established Mexican pharmaceutical
company with over 80 years in the Mexican market. They have a US
FDA-approved state-of-the-art manufacturing facility for creams and
ointments and are one of the top 10 Mexican pharmaceutical
manufacturers.
Safe Harbor Statement: Statements about
the Company's future expectations and all other statements in this
press release other than historical facts, are "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934, and as
that term is defined in the Private Securities Litigation Reform
Act of 1995. The Company intends that such forward-looking
statements be subject to the safe harbors created thereby.
The above information contains information relating to the
Company that is based on the beliefs of the Company and/or its
management, as well as assumptions made by any information
currently available to the Company or its management. When used in
this document, the words "anticipate," "estimate," "expect,"
"intend," "plans," "projects," and similar expressions, as they
relate to the Company or its management, are intended to identify
forward-looking statements. Such statements reflect the current
view of the Company regarding future events and are subject to
certain risks, uncertainties and assumptions, including the risks
and uncertainties noted. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove
to be incorrect, actual results may vary materially from those
described herein as anticipated, believed, estimated, expected,
intended or projected. In each instance, forward-looking
information should be considered in light of the accompanying
meaningful cautionary statements herein. Factors that could cause
results to differ include, but are not limited to, successful
performance of internal plans, the impact of competitive services
and pricing and general economic risks and uncertainties.
Contact: Investor Relations Taylor Capitol, Inc. Stephen Taylor
(973) 351-3868 STEPHTAYL9@AOL.COM www.TheStockAlerts.com
Allstar Health Brands (PK) (USOTC:ALST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allstar Health Brands (PK) (USOTC:ALST)
Historical Stock Chart
From Jul 2023 to Jul 2024